Evidence map›Paper›PMID 35929483›Full record

ReviewDiabetes, obesity & metabolism2022

Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan.

Takashi Kadowaki, Hiroshi Maegawa, Hirotaka Watada, Daisuke Yabe, Koichi Node, Toyoaki Murohara, Jun Wada

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Diabetes, obesity & metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed
18.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 154 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Early signs of nephropathy in adolescents with obesity.International journal of obesity (2005) · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 1 country.

Takashi KadowakiToranomon Hospital, Tokyo, Japan.
Hiroshi MaegawaYasu City Hospital, Shiga, Japan.ORCID 0000-0002-4611-8149
Hirotaka WatadaDepartment of Metabolism and Endocrinology, Juntendo University, Tokyo, Japan.ORCID 0000-0001-5961-1816
Daisuke YabeDepartment of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.ORCID 0000-0002-5334-7687
Koichi NodeDepartment of Cardiovascular Medicine, Saga University, Saga, Japan.ORCID 0000-0002-2534-0939
Toyoaki MuroharaDepartment of Cardiology, Nagoya University, Nagoya, Japan.
Jun WadaDepartment of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University, Okayama, Japan.ORCID 0000-0003-1468-5170
Juntendo University · JPNagoya University · JPOkayama University · JPSaga University · JPShiga University of Medical Science Hospital · JPTokai Gakuen University · JPToranomon Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insights from epidemiological, clinical and basic research are illuminating the interplay between metabolic disorders, cardiovascular disease (CVD) and kidney dysfunction, termed cardio-renal-metabolic (CRM) disease. Broadly defined, CRM disease involves multidirectional interactions between metabolic diseases such as type 2 diabetes (T2D), various types of CVD and chronic kidney disease (CKD). T2D confers increased risk for heart failure, which-although well known-has only recently come into focus for treatment, and may differ by ethnicity, whereas atherosclerotic heart disease is a well-established complication of T2D. Many people with T2D also have CKD, with a higher risk in Asians than their Western counterparts. Furthermore, CVD increases the risk of CKD and vice versa, with heart failure, notably, present in approximately half of CKD patients. Molecular mechanisms involved in CRM disease include hyperglycaemia, insulin resistance, hyperactivity of the renin-angiotensin-aldosterone system, production of advanced glycation end-products, oxidative stress, lipotoxicity, endoplasmic reticulum stress, calcium-handling abnormalities, mitochondrial malfunction and deficient energy production, and chronic inflammation. Pathophysiological manifestations of these processes include diabetic cardiomyopathy, vascular endothelial dysfunction, cardiac and renal fibrosis, glomerular hyperfiltration, renal hypoperfusion and venous congestion, reduced exercise tolerance leading to metabolic dysfunction, and calcification of atherosclerotic plaque. Importantly, recognition of the interaction between CRM diseases would enable a more holistic approach to CRM care, rather than isolated treatment of individual conditions, which may improve patient outcomes. Finally, aspects of CRM diseases may differ between Western and East Asian countries such as Japan, a super-ageing country, with potential differences in epidemiology, complications and prognosis that represent an important avenue for future research.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Heart FailureMetabolic DiseasesRenal Insufficiency, ChronicHumansJapanKidneycardiovascular diseasediabetic nephropathyheart failuretype 2 diabetes

Identifiers

PMID35929483
OpenAlexW4289869385

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.